Y.S.P.SOUTHEAST ASIA HOLDING
KLSE (MYR): YSPSAH (7178)
You're accessing 15 mins delay data. Turn on live stream now to enjoy real-time data!
Last Price
2.40
Today's Change
0.00 (0.00%)
Day's Change
2.40 - 2.41
Trading Volume
17,400
Financial
Market Cap
340 Million
NOSH
142 Million
Latest Quarter
30-Jun-2024 [#2]
Announcement Date
20-Aug-2024
Next Quarter
30-Sep-2024
Est. Ann. Date
21-Nov-2024
Est. Ann. Due Date
29-Nov-2024
QoQ | YoY
-76.87% | -74.15%
Revenue | NP to SH
364,545.000 | 31,154.000
RPS | P/RPS
257.00 Cent | 0.93
EPS | P/E | EY
21.96 Cent | 10.93 | 9.15%
DPS | DY | Payout %
11.00 Cent | 4.58% | 50.08%
NAPS | P/NAPS
2.81 | 0.85
QoQ | YoY
-22.76% | -22.25%
NP Margin | ROE
8.65% | 7.82%
F.Y. | Ann. Date
30-Jun-2024 | 20-Aug-2024
Latest Audited Result
31-Dec-2023
Announcement Date
23-Apr-2024
Next Audited Result
31-Dec-2024
Est. Ann. Date
23-Apr-2025
Est. Ann. Due Date
29-Jun-2025
Revenue | NP to SH
354,995.000 | 37,315.000
RPS | P/RPS
250.27 Cent | 0.96
EPS | P/E | EY
26.31 Cent | 9.12 | 10.96%
DPS | DY | Payout %
10.00 Cent | 4.17% | 38.01%
NAPS | P/NAPS
2.79 | 0.86
YoY
8.27%
NP Margin | ROE
10.66% | 9.43%
F.Y. | Ann. Date
31-Dec-2023 | 27-Feb-2024
Revenue | NP to SH
369,532.000 | 34,064.000
RPS | P/RPS
260.52 Cent | 0.92
EPS | P/E | EY
24.02 Cent | 9.99 | 10.01%
DPS | DY | Payout %
-
NAPS | P/NAPS
-
QoQ | YoY
-38.43% | -26.56%
NP Margin | ROE
9.41% | 8.55%
F.Y. | Ann. Date
30-Jun-2024 | 20-Aug-2024
Show?
| Last 10 FY Result | ||||||||||||||
| AQR | T4Q | 31/12/23 | 31/12/22 | 31/12/21 | 31/12/20 | 31/12/19 | 31/12/18 | 31/12/17 | 31/12/16 | 31/12/15 | 31/12/14 | CAGR | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 369,532 | 364,545 | 354,995 | 334,248 | 281,860 | 297,061 | 295,619 | 288,759 | 261,556 | 237,065 | 222,925 | 202,226 | 6.44% | |
| PBT | 52,030 | 48,494 | 53,822 | 47,693 | 22,493 | 30,263 | 31,832 | 42,304 | 29,688 | 36,317 | 39,527 | 25,230 | 8.77% | |
| Tax | -17,246 | -16,944 | -15,997 | -12,920 | -7,392 | -8,104 | -9,354 | -12,171 | -9,624 | -8,399 | -10,154 | -8,139 | 7.79% | |
| NP | 34,784 | 31,550 | 37,825 | 34,773 | 15,101 | 22,159 | 22,478 | 30,133 | 20,064 | 27,918 | 29,373 | 17,091 | 9.22% | |
| - | ||||||||||||||
| NP to SH | 34,064 | 31,154 | 37,315 | 34,466 | 15,182 | 21,976 | 23,012 | 30,350 | 20,382 | 27,594 | 28,968 | 16,492 | 9.49% | |
| - | ||||||||||||||
| Tax Rate | 33.15% | 34.94% | 29.72% | 27.09% | 32.86% | 26.78% | 29.39% | 28.77% | 32.42% | 23.13% | 25.69% | 32.26% | - | |
| Total Cost | 334,748 | 332,995 | 317,170 | 299,475 | 266,759 | 274,902 | 273,141 | 258,626 | 241,492 | 209,147 | 193,552 | 185,135 | 6.16% | |
| - | ||||||||||||||
| Net Worth | 398,584 | 398,584 | 395,691 | 372,290 | 343,721 | 341,901 | 328,027 | 315,262 | 289,871 | 274,727 | 256,898 | 235,410 | 5.93% | |
| Dividend | ||||||||||||||
| AQR | T4Q | 31/12/23 | 31/12/22 | 31/12/21 | 31/12/20 | 31/12/19 | 31/12/18 | 31/12/17 | 31/12/16 | 31/12/15 | 31/12/14 | CAGR | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Div | 31,205 | 15,602 | 14,182 | 11,281 | 11,177 | 11,256 | 11,864 | 9,679 | 11,622 | 10,773 | 8,697 | 8,645 | 5.65% | |
| Div Payout % | 91.61% | 50.08% | 38.01% | 32.73% | 73.63% | 51.22% | 51.56% | 31.89% | 57.02% | 39.04% | 30.02% | 52.42% | - | |
| Equity | ||||||||||||||
| AQR | T4Q | 31/12/23 | 31/12/22 | 31/12/21 | 31/12/20 | 31/12/19 | 31/12/18 | 31/12/17 | 31/12/16 | 31/12/15 | 31/12/14 | CAGR | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Worth | 398,584 | 398,584 | 395,691 | 372,290 | 343,721 | 341,901 | 328,027 | 315,262 | 289,871 | 274,727 | 256,898 | 235,410 | 5.93% | |
| NOSH | 141,844 | 141,844 | 141,844 | 141,034 | 140,899 | 140,700 | 139,583 | 138,301 | 136,746 | 134,670 | 133,801 | 133,000 | 0.71% | |
| Ratio Analysis | ||||||||||||||
| AQR | T4Q | 31/12/23 | 31/12/22 | 31/12/21 | 31/12/20 | 31/12/19 | 31/12/18 | 31/12/17 | 31/12/16 | 31/12/15 | 31/12/14 | CAGR | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NP Margin | 9.41% | 8.65% | 10.66% | 10.40% | 5.36% | 7.46% | 7.60% | 10.44% | 7.67% | 11.78% | 13.18% | 8.45% | - | |
| ROE | 8.55% | 7.82% | 9.43% | 9.26% | 4.42% | 6.43% | 7.02% | 9.63% | 7.03% | 10.04% | 11.28% | 7.01% | - | |
| Per Share | ||||||||||||||
| AQR | T4Q | 31/12/23 | 31/12/22 | 31/12/21 | 31/12/20 | 31/12/19 | 31/12/18 | 31/12/17 | 31/12/16 | 31/12/15 | 31/12/14 | CAGR | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RPS | 260.52 | 257.00 | 250.30 | 237.02 | 201.73 | 211.13 | 211.78 | 208.83 | 191.29 | 176.03 | 166.61 | 152.05 | 5.69% | |
| EPS | 24.02 | 21.96 | 26.37 | 24.45 | 10.87 | 15.68 | 16.54 | 22.05 | 15.01 | 20.49 | 21.65 | 12.40 | 8.73% | |
| DPS | 22.00 | 11.00 | 10.00 | 8.00 | 8.00 | 8.00 | 8.50 | 7.00 | 8.50 | 8.00 | 6.50 | 6.50 | 4.89% | |
| NAPS | 2.81 | 2.81 | 2.79 | 2.64 | 2.46 | 2.43 | 2.35 | 2.28 | 2.12 | 2.04 | 1.92 | 1.77 | 5.18% | |
| Adjusted Per Share Value based on latest NOSH - 141,844 | ||||||||||||||
| AQR | T4Q | 31/12/23 | 31/12/22 | 31/12/21 | 31/12/20 | 31/12/19 | 31/12/18 | 31/12/17 | 31/12/16 | 31/12/15 | 31/12/14 | CAGR | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RPS | 260.52 | 257.00 | 250.27 | 235.64 | 198.71 | 209.43 | 208.41 | 203.57 | 184.40 | 167.13 | 157.16 | 142.57 | 6.44% | |
| EPS | 24.02 | 21.96 | 26.31 | 24.30 | 10.70 | 15.49 | 16.22 | 21.40 | 14.37 | 19.45 | 20.42 | 11.63 | 9.48% | |
| DPS | 22.00 | 11.00 | 10.00 | 7.95 | 7.88 | 7.94 | 8.36 | 6.82 | 8.19 | 7.60 | 6.13 | 6.09 | 5.66% | |
| NAPS | 2.81 | 2.81 | 2.7896 | 2.6246 | 2.4232 | 2.4104 | 2.3126 | 2.2226 | 2.0436 | 1.9368 | 1.8111 | 1.6596 | 5.93% | |
| Price Multiplier on Financial Quarter End Date | ||||||||||||||
| AQR | T4Q | 31/12/23 | 31/12/22 | 31/12/21 | 31/12/20 | 31/12/19 | 31/12/18 | 31/12/17 | 31/12/16 | 31/12/15 | 31/12/14 | CAGR | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Date | 28/06/24 | 28/06/24 | 29/12/23 | 30/12/22 | 31/12/21 | 31/12/20 | 31/12/19 | 31/12/18 | 29/12/17 | 30/12/16 | 31/12/15 | 31/12/14 | - | |
| Price | 2.82 | 2.82 | 2.30 | 2.55 | 1.93 | 2.28 | 2.33 | 2.75 | 2.69 | 1.91 | 2.48 | 1.30 | - | |
| P/RPS | 1.08 | 1.10 | 0.92 | 1.08 | 0.96 | 1.08 | 1.10 | 1.32 | 1.41 | 1.09 | 1.49 | 0.85 | 0.88% | |
| P/EPS | 11.74 | 12.84 | 8.74 | 10.43 | 17.76 | 14.60 | 14.13 | 12.53 | 18.05 | 9.32 | 11.45 | 10.48 | -1.99% | |
| EY | 8.52 | 7.79 | 11.44 | 9.58 | 5.63 | 6.85 | 7.08 | 7.98 | 5.54 | 10.73 | 8.73 | 9.54 | 2.03% | |
| DY | 7.80 | 3.90 | 4.35 | 3.14 | 4.15 | 3.51 | 3.65 | 2.55 | 3.16 | 4.19 | 2.62 | 5.00 | -1.53% | |
| P/NAPS | 1.00 | 1.00 | 0.82 | 0.97 | 0.78 | 0.94 | 0.99 | 1.21 | 1.27 | 0.94 | 1.29 | 0.73 | 1.29% | |
| Price Multiplier on Announcement Date | ||||||||||||||
| AQR | T4Q | 31/12/23 | 31/12/22 | 31/12/21 | 31/12/20 | 31/12/19 | 31/12/18 | 31/12/17 | 31/12/16 | 31/12/15 | 31/12/14 | CAGR | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Date | 20/08/24 | 20/08/24 | 27/02/24 | 27/02/23 | 25/02/22 | 25/02/21 | 25/02/20 | 26/02/19 | 28/02/18 | 22/02/17 | 26/02/16 | 27/02/15 | - | |
| Price | 2.77 | 2.77 | 2.38 | 2.92 | 1.93 | 2.16 | 2.21 | 2.88 | 2.52 | 2.09 | 2.61 | 1.50 | - | |
| P/RPS | 1.06 | 1.08 | 0.95 | 1.23 | 0.96 | 1.02 | 1.04 | 1.38 | 1.32 | 1.19 | 1.57 | 0.99 | -0.45% | |
| P/EPS | 11.53 | 12.61 | 9.05 | 11.95 | 17.76 | 13.83 | 13.41 | 13.12 | 16.91 | 10.20 | 12.06 | 12.10 | -3.17% | |
| EY | 8.67 | 7.93 | 11.05 | 8.37 | 5.63 | 7.23 | 7.46 | 7.62 | 5.92 | 9.80 | 8.30 | 8.27 | 3.27% | |
| DY | 7.94 | 3.97 | 4.20 | 2.74 | 4.15 | 3.70 | 3.85 | 2.43 | 3.37 | 3.83 | 2.49 | 4.33 | -0.33% | |
| P/NAPS | 0.99 | 0.99 | 0.85 | 1.11 | 0.78 | 0.89 | 0.94 | 1.26 | 1.19 | 1.02 | 1.36 | 0.85 | 0.00% | |
PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.
NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.
Div Payout %, NP Margin, ROE, DY, QoQ ⃤ & YoY ⃤ figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.
All figures in '000 unless specified.
Discussions
6 people like this. Showing 50 of 2,085 comments
Hold for lomg term.
2 years like that.
You will thanks me.
Just a cup of starbuck belanja me.
2021-09-22 11:31
Guide to Investing in Bursa Healthcare 2022
1. Kotra Industries 2. YSP 3. ???
2022-04-02 21:53
Buy-side has no more idea. They will pump all the healthcare stocks remaining
2022-11-04 11:22
walao ehh..wat happen to YSP
Suddenly surge to fly so high today!! Happy Happy
2022-12-13 12:48
Finally this share has released it's true potential power. I have been waiting years for it to shine
2023-01-03 19:55
Apex Healthcare + YSP + Kotra Industries = Dream Healthcare Portfolio 2023
2023-02-23 16:34
Integrity. Intelligent. Industrious. 3iii (iiinvestsmart)$â¬Â£Â¥
Security LastPr PE DY% Divcts ROE ttm-marg
YSPSAH (Pharmaceuticals) 2.35 9.63 3.4 8 9.25 10.3
2023-03-30 17:12
New Production line is started to be operated for the newly acquired factory premise. With the newly operated production line, the company's Revenue YoY % growth will be significantly increased within 2 years.
2024-05-22 18:51
Hi BullishMarket, from where you aware that New Production line is started to be operated for the newly acquired factory premise?
2024-05-22 20:15
bought a few at 2.85, acceptable bargain I think considering today open at RM3
2024-05-23 11:41
https://www.facebook.com/xngyuan/videos/828026755888524?idorvanity=3251240861803724
chenjian sifu commented YSPSAH positively
2024-06-03 22:07
reasons to buy:
1. recorded highest revenue and profit in 20years
2. organic growth, hold patents (expect to continue deliver good result)
3. DY 3.5% above RM0.11 ex 24/6/24
let's monitor
😎
2024-06-04 15:45
Yspsah has been all the while being the lowest valuation company against its peers like Ahealth & Dpharma.
2024-06-06 10:44
https://www.ctee.com.tw/news/20220714700772-439801
永信東南亞控股是台灣本土學名藥製藥廠中，第一家跨國上市的公司。這兩年，受疫情影響，年營收成長仍有3％〜5％。即將來臨的後疫情時代，李芳信預計，自2022年起，公司營收至少有雙位數以上的成長。
2024-07-04 13:57
sold all YSPSAH at open price of 2.35 after very disaapointing QR (9.00am, 21 august 2024)
2 months ago
For the first half of 2024, the Group's revenue rose 5.5% to RM184.8 million compared to RM175.2 million reported in the same period last year. The Group's profit before tax for 1H24 declined 17.0% to RM26.0 million from RM31.3 million in 1H23 due to higher unrealised foreign exchange loss was recorded resulted from strengthening of US Dollar.
Therefore, does that mean the stronger ringgit is in favour of YSP?
2 months ago
For the first half of 2023, the Group recorded a profit before tax of RM31.3 million compared to RM24.4 million in the same period last year mainly due to higher sales
from domestic and overseas market and foreign exchange gain resulted from weakening of the Ringgit against the US Dollar.
--Q2 2023😁
2 months ago
Katara, thanks! I guess it depends on the mix/geography of the sales. Anyway, good to see seriously buyback this round by Lees.
2 months ago
Post a Comment
Featured Posts
Latest Videos
MQ Trading Signals
Time
Signal
Duration
Type
2024-11-08 16:00:00
EMA 5
10 Mins
SELL
2024-11-08 15:55:00
EMA 5
5 Mins
SELL
2024-11-08 15:50:00
ADX
10 Mins
SELL
2024-11-08 15:50:00
TURTLE SYSTEM 20
10 Mins
SELL
2024-11-08 15:50:00
ADX
5 Mins
SELL
Apps
Top Articles
1
2
save malaysia!
3
Good Articles to Share
Trump win to test limit of presidential power; Harris concedes but vows 'fight'
5
6
BFM Podcast
7
BFM Podcast
8
BFM Podcast
#
Stock
Score
Daily Stocks
Stock Name
Last
Change
Volume
Stock Name
Last
Change
Volume
Stock Name
Last
Change
Volume
Featured Advertisers / Partners
Ride The Bull Short The Bear
CS Tan
4.9 / 5.0
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
ValueMe
Hold sampai tumbuh janggut putih.Kihkihkih.
2021-09-18 15:04